New drug cocktail aims to crush resistant leukemia

NCT ID NCT06466122

Recruiting now Disease control Sponsor: Kerry Rogers Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining pirtobrutinib and venetoclax can eliminate signs of cancer in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has stopped responding to standard BTK inhibitors. About 30 adults currently taking ibrutinib, acalabrutinib, or zanubrutinib but with worsening disease will receive the two oral drugs. The main goal is to see how many achieve undetectable minimal residual disease in blood and bone marrow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pirtobrutinib and venetoclax
What this could lead to: If successful, this combination could offer a new treatment option for CLL/SLL patients whose cancer has stopped responding to standard BTK inhibitors.
What could go wrong: This is a small, early-phase trial with only 30 participants. The combination may not work for everyone, and side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.